Taysha reports 2023 net loss of $111.6M; TSHA-102 shows sustained improvements in Rett patients

Taysha Gene Therapies, Inc.

Revenue of $15.5M for full-year 2023 (up from $2.5M in 2022) from Astellas option agreement.
Net loss of $111.6M ($0.96 loss per basic share) vs. $166.0M ($3.78/share) in 2022; includes $34.5M non-cash warrant expense.
Cash and equivalents of $143.9M as of Dec 31, 2023; cash runway expected into 2026.
TSHA-102 low dose (5.7x10^14 vg) in REVEAL adult trial: well-tolerated, no SAEs; patient 1 shows improved sitting, sleep, social interaction at week 35; patient 2 shows reduced seizures at week 19.
IDMC approved early dose escalation to high dose (1x10^15 vg) in adult/pediatric trials; initial pediatric low-dose data due mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Taysha Gene Therapies, Inc. reported financial results for Full Year 2023.

Period: Full Year 2023
Result: reported results

Exact text from the filing

On March 19, 2024, Taysha Gene Therapies, Inc. (the " Company ") reported financial results for the year ended December 31, 2023 and recent business and clinical updates.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-071321

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.